Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2020-003072-41 | EudraCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Bayer | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
The aim of this study is to evaluate the prevalence of osteoporosis in adult patients with haemophilia.
The aim of this study is to evaluate the prevalence of osteoporosis in adult patients with haemophilia. Subsequently, the ascertained prevalence of osteoporosis in patients with haemophilia will be compared to the latest published data of osteoporosis in Germany. Furthermore, the impact of severity of haemophilia, comorbidities as well as the role of both physical activity and individual joint condition as influencing factors on the presence of osteoporosis will be analysed by this study.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients with mild haemophilia A or B | (FVIII or IX >5 %, ≥ 18 years' old) | ||
| Patients with moderate haemophilia A or B | (FVIII or IX 1-5 %, ≥ 18 years' old) | ||
| Patients with severe haemophilia A or B | (FVIII or IX <1 %, ≥ 18 years' old) |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| bone mass/bone density maesurement | All patients with haemophilia of this study will receive a standardised bone density measurement by using the same dual energy X-ray absorptiometry (DXA) device. | 15 minutes |
| blood sample (Vit. D/Calcium) | The blood samples of all patients with haemophilia will be tested according to the guidelines of the confederation of osteology (DVO). These blood samples are necessary to assess the osteoporosis by measuring the Vitamin-D and Calcium level. | 10 minutes |
| Measure | Description | Time Frame |
|---|---|---|
| haemophilia related clinical data | All patients with haemophilia record their individual substitution regime and bleeding events in individual patients' diaries. The patients are used to record and submit all necessary information about bleeding events, factor replacement regime. By doing so, the individual treatment regime per week as well as the annual (joint) bleeding rate will be assessed one year retrospectively. |
| Measure | Description | Time Frame |
|---|---|---|
| blood samples | Blood samples of all PWH will be tested according to the guidelines of the confederation of osteology (DVO). Additionally, the liver's (GGT, GPT, GOT) and parathyroid glands' (PTH) function will be assessed and patient's will also be tested for testosterone-deficiency (testosterone), diabetes (HbA1c) and multiple myeloma (paracentesis). Furthermore these blood samples are necessary to define the immune phenotype (including: soluble mediators such as cytokines and growth factors, as well as the cellular immune composition, immune cell subsets and their detailed phenotype) to examine a possible correlation with the severity of osteoporosis. |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Adult patients (≥ 18 years of age) suffering from mild (FVIII or IX >5 %), moderate (FVIII or IX 1-5 %) or severe (FVIII or IX <1 %) haemophilia A or B
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Andreas Strauß, PD Dr. | Contact | 004922828714176 | andreas.strauss@ukbonn.de |
| Name | Affiliation | Role |
|---|---|---|
| Andreas Strauß, PD Dr. | Medicine of the University of Bonn | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University Hospital of Bonn | Recruiting | Bonn | Northrhine Westfalia | 53127 | Germany |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 40138293 | Derived | Ransmann P, Bruhl M, Hmida J, Goldmann G, Oldenburg J, Schildberg FA, Ossendorff R, Tomschi F, Schmidt A, Hilberg T, Strauss AC. Physical activity and handgrip strength in patients with mild, moderate and severe haemophilia: Impacts on bone quality and lean mass. PLoS One. 2025 Mar 26;20(3):e0319951. doi: 10.1371/journal.pone.0319951. eCollection 2025. |
Not provided
Not provided
The publication of anonymous patient data is not allowed by informed consent.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D010024 | Osteoporosis |
| D006467 | Hemophilia A |
| ID | Term |
|---|---|
| D001851 | Bone Diseases, Metabolic |
| D001847 | Bone Diseases |
| D009140 | Musculoskeletal Diseases |
| D008659 | Metabolic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| 10 minutes |
| level of physical activity | In order to assess the individual level of physical activity, an individual movement profile will be created. For this purpose, the activity of each patient with haemophilia will be recorded by an electronic activity tracker. In addition, the grade of individual physical activity will be assessed on the basis of questionnaires. | non determinable |
| orthopaedic joint status | The clinical joint status will be examined in all patients with haemophilia by the World Federation Joint Examination Score and Haemophilia Joint Health Score. | 45 minutes |
| pain condition | The pain condition will be examined in terms of pressure pain thresholds. By using an algometer device (Wagner Instruments, USA) with a robe area of 1 cm2 the individual pain sensitivity will be measured. | 15 minutes |
| subjective quality of life and subjective physical performance | The examination of these parameters is carried out by the standardised questionnaires SF-36 (quality of life) and the HEP-Test-Q (subjective physical performance). | 10 minutes |
| non determinable |
| Medical history | Medical history and pharmacological treatment will be recorded. Based on these parameters the occurrence of secondary osteoporosis will be assessed. | 10 minutes |
| D009750 |
| Nutritional and Metabolic Diseases |
| D025861 | Blood Coagulation Disorders, Inherited |
| D001778 | Blood Coagulation Disorders |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D020147 | Coagulation Protein Disorders |
| D006474 | Hemorrhagic Disorders |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |